Pharsight

Vraylar generic

Vraylar is an antipsychotic medication owned by Abbvie, which was first given market authorization on 17 September, 2015. The drug is formulated with the active ingredient cariprazine hydrochloride and is available in capsule and oral forms. Vraylar holds a total of 5 patents.

When will Vraylar generic be available?

The generic version of Vraylar is expected to be released after 17 September, 2029. The last patent, labeled as US7737142 and titled as '(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists', is set to expire on 17 September 2029. Hence the earliest generic launch can happen only post this date.

Vraylar uses

Vraylar is used for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. The active ingredient, Cariprazine, plays a key role by serving as a dopamine receptor ligand, which helps in managing the imbalances of dopamine levels, often seen in these disorders. It is also used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

Vraylar patent expiration

Vraylar holds 5 patents, with the latest one, US7737142 titled '(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists', set to expire on 17 September, 2029. Upon the expiration of this patent, the Vraylar generic can be made available in the market. Below is the detail of the patent:

Vraylar dosage

Want to ask something?